DDInter923 DDInter172
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Infliximab may lead to a major life threatening interaction when taken with Aldesleukin